Schizophrenia Market Research Report - Global Forecast till 2027

Schizophrenia Market Research Report: Information by Type (Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia), Treatment {Second-Generation Antipsychotics [Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone)], Third-Generation Antipsychotics and others}, Route of Administration (Oral and Injectables) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/1094-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2019–2025 to 2020-2027. Cordially fill Sample form for updated data.

Market Scenario


Schizophrenia Market is projected to reach USD 7.2 Billion in 2018 and expected to register a 2.5% CAGR during the forecast period. Schizophrenia is a long-term mental disorder involving a breakdown in the relation between thought, emotion, and behavior. Although the course of schizophrenia varies among individuals, it is typically persistent and can be both severe and disabling.


The primary factors driving the growth of the global schizophrenia market are rising cases of schizophrenia, a growing number of geriatric individuals, and increasing research and development in schizophrenia treatment. According to the National Institute of Mental Health (NIMH), schizophrenia is one of the top 15 leading causes of disability worldwide. According to the Schizophrenia and Related Disorders Alliance of America, schizophrenia can be found in approximately 1.1% of the world’s population, regardless of racial, ethnic, or economic background. However, stringent regulations around new product approvals and rising generic launches are hampering the growth of the global market.


Segmentation


The Global Schizophrenia Market has been segmented into type, treatment, and route of administration.


By type, the global market has been segmented into paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, and undifferentiated schizophrenia.


 Based on treatment, the global market has been divided into second-generation antipsychotics and third-generation antipsychotics. The second-generation antipsychotics segment is further sub-segmented into Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone), and others.


Based on route of administration, the global market has been bifurcated into oral and injectables.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The schizophrenia market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European schizophrenia market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The schizophrenia market in Asia-Pacific has been segmented into Japan, China, India, Latin Korea, Australia, and the rest of Asia-Pacific. The schizophrenia market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key Players


Johnson & Johnson (US), Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals (US), AstraZeneca (UK), Eli Lilly (US), Alkermes (Ireland), Sumitomo Dainippon Pharma (Japan)             


Pfizer (US), Vanda Pharmaceuticals (US), and Allergan/Geodon Ritcher (Ireland) are some of the key players operating in the global schizophrenia market.


Regional Market Summary


Global Schizophrenia Market Share (%), by Region, 2018  Schizophrenia Market


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. It is estimated that Americas dominated the global schizophrenia market owing to the increasing prevalence of schizophrenia, growing geriatric population, and rising demand for schizophrenia treatment. According to the Treatment Advocacy Center, schizophrenia is a chronic and severe neurological brain disorder that affected approximately 2.6 million adults in the US aged 18 or older in 2015. Additionally, rising awareness programs are driving the growth of the market. Mental Health America (MHA) has created an initiative entitled B4Stage4 designed to foster awareness and early identification/intervention for mental illness.


The market in Europe is expected to hold the second-largest share owing to the increasing health problems and rising older population. Additionally, increasing healthcare expenditure is driving the regional market growth. For instance, according to the European Commission, in the Member States of the European Union the cost of mental health problems is estimated to be between 3%and 4% of the gross national product. 


Asia-Pacific is expected to be a rapidly growing region in the schizophrenia market. The market is expected to witness growth owing to the increasing population and rising demand for technologically advanced treatments. The prevalence of mental illness is high in developing countries and cities, such as Japan, Hong Kong, and Singapore, support market growth.


The market in the Middle East & Africa holds a low share in the schizophrenia market due to the presence of a low number of healthcare facilities, low per capita income, and people living in underdeveloped countries are not much aware of the upcoming treatment methods. However, the market is expected to witness growth due to increasing hospitals and rising demand for schizophrenia treatment products in the Middle East.


Global Schizophrenia Market, by Type



  • Paranoid Schizophrenia

  • Hebephrenic Schizophrenia

  • Catatonic Schizophrenia

  • Undifferentiated Schizophrenia


Global Schizophrenia Market, by Treatment  



  • Second-Generation Antipsychotics

    • Risperdal (Risperidone)

    • Invega (Paliperidone)

    • Zyprexa (Olanzapine)

    • Geodon (Ziprasidone)

    • Seroquel (Quetiapine)

    • Latuda (Lurasidone)

    • Others



  • Third-Generation Antipsychotics

    • Others




Global Schizophrenia Market, by Route of Administration



  • Oral

  • Injectables


Global Schizophrenia Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • Latin Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Mental illness treatment centers

  • Contract research organizations (CROs)

  • Research and development (R&D) companies

  • Government research laboratories

  • Independent research laboratories

  • Government and independent regulatory authorities

  • Market research and consulting service providers

  • Medical research laboratories

  • Academic medical institutes and universities



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 7.2 Billion
  • 2027: Significant Value
  •   CAGR   2.5% (2019–2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Treatment and Route of Administration
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Johnson & Johnson (US), Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals (US), AstraZeneca (UK), Eli Lilly (US), Alkermes (Ireland), Sumitomo Dainippon Pharma (Japan), Pfizer (US), Vanda Pharmaceuticals (US), and Allergan/Geodon Ritcher (Ireland)
      Key Market Opportunities   stringent regulations around new product approvals and rising generic launches
      Key Market Drivers

  • rising cases of schizophrenia
  • growing number of geriatric individuals
  • increasing research and development in schizophrenia treatment


  • Frequently Asked Questions (FAQ) :


    Schizophrenia Market can expand at 2.5% CAGR from 2019 to 2025.

    The Global Schizophrenia Market stood at USD 7.2 billion in 2018.

    Developments in schizophrenia treatment, rising cases of the disorder, and the growing numbers of the geriatric populace are major drivers of the Global Schizophrenia Market.

    The Global Schizophrenia Market growth can be hampered by generic launches and approvals of new products.

    Alkermes, Allergan/Geodon Ritcher, Johnson & Johnson, AstraZeneca, Eli Lilly, Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals, Pfizer, Sumitomo Dainippon Pharma, and Vanda Pharmaceuticals are prominent players of the Global Schizophrenia Market.

    Table of Contents

    1. REPORT PROLOGUE

    2. MARKET INTRODUCTION

    2.1. Definition

    2.2. Scope of the Study

    2.2.1. Research Objective

    2.2.2. Assumptions

    2.2.3. Limitations

    3. RESEARCH METHODOLOGY

    3.1. Overview

    3.2. Primary Research

    3.3. Secondary Research

    3.4. Market Size Estimation

    4. MARKET DYNAMICS

    4.1. Overview

    4.2. Drivers

    4.3. Restraints

    4.4. Opportunities

    5. MARKET FACTOR ANALYSIS

    5.1. Porter’s Five Forces Analysis

    5.1.1. Bargaining Power of Suppliers

    5.1.2. Bargaining Power of Buyers

    5.1.3. Threat of New Entrants

    5.1.4. Threat of Substitutes

    5.1.5. Intensity of Rivalry

    5.2. Value Chain Analysis


    6. GLOBAL SCHIZOPHRENIA MARKET, BY TYPE

    6.1. Overview

    6.2. Paranoid schizophrenia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3. Hebephrenic schizophrenia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4. Catatonic schizophrenia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5. Undifferentiated schizophrenia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7. GLOBAL SCHIZOPHRENIA MARKET, BY TREATMENT

    7.1. Overview

    7.2. Second-Generation Antipsychotics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.1. Risperdal (Risperidone)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.2. Invega (Paliperidone)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.3. Zyprexa (Olanzapine)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.4. Geodon (Ziprasidone)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.5. Seroquel (Quetiapine)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.6. Latuda (Lurasidone)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.7. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3. Third-Generation Antipsychotics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8. GLOBAL SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION

    8.1. Overview

    8.2. Oral

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3. Injectables

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9. GLOBAL SCHIZOPHRENIA MARKET, BY REGION

    9.1. Overview

    9.2. Americas

    9.2.1. North America

    9.2.1.1. US

    9.2.1.2. Canada

    9.2.2. Latin America

    9.3. Europe

    9.3.1. Western Europe

    9.3.1.1. Germany

    9.3.1.2. France

    9.3.1.3. Italy

    9.3.1.4. Spain

    9.3.1.5. UK

    9.3.1.6. Rest of Western Europe

    9.3.2. Eastern Europe

    9.4. Asia-Pacific

    9.4.1. Japan

    9.4.2. China

    9.4.3. India

    9.4.4. Australia

    9.4.5. South Korea

    9.4.6. Rest of Asia-Pacific

    9.5. Middle East & Africa

    9.5.1. Middle East

    9.5.2. Africa

    10. COMPANY LANDSCAPE

    10.1. Overview

    10.2. Competitive Analysis

    10.3. Market Share Analysis

    10.4. Major Growth Strategy in the Global Schizophrenia Market

    10.5. Competitive Benchmarking

    10.6. Leading Players in Terms of Number of Developments in the Global Schizophrenia Market

    10.7. Key developments and Growth Strategies

    10.7.1. Product Launch/Service Deployment

    10.7.2. Mergers and Acquisitions

    10.7.3. Joint Ventures

    10.8. Major Players Financial Matrix & Market Ratio

    10.8.1. Sales & Operating Income 2020

    10.8.2. Major Players R&D Expenditure 2020

    10.9. Major Players Capital Market Ratio

    11. COMPANY PROFILES

    11.1. Johnson & Johnson

    11.1.1. Company Overview

    11.1.2. Product Overview

    11.1.3. Financial Overview

    11.1.4. Key Developments

    11.1.5. SWOT Analysis

    11.1.6. Key Strategies

    11.2. Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals

    11.2.1. Company Overview

    11.2.2. Product Overview

    11.2.3. Financial Overview

    11.2.4. Key Developments

    11.2.5. SWOT Analysis

    11.2.6. Key Strategies

    11.3. AstraZeneca

    11.3.1. Company Overview

    11.3.2. Product Overview

    11.3.3. Financial Overview

    11.3.4. Key Developments

    11.3.5. SWOT Analysis

    11.3.6. Key Strategies

    11.4. Eli Lilly

    11.4.1. Company Overview

    11.4.2. Product Overview

    11.4.3. Financial Overview

    11.4.4. Key Developments

    11.4.5. SWOT Analysis

    11.4.6. Key Strategies

    11.5. Alkermes

    11.5.1. Company Overview

    11.5.2. Product Overview

    11.5.3. Financial Overview

    11.5.4. Key Developments

    11.5.5. SWOT Analysis

    11.5.6. Key Strategies

    11.6. Sumitomo Dainippon Pharma

    11.6.1. Company Overview

    11.6.2. Product Overview

    11.6.3. Financial Overview

    11.6.4. Key Developments

    11.6.5. SWOT Analysis

    11.6.6. Key Strategies

    11.7. Pfizer

    11.7.1. Company Overview

    11.7.2. Product Overview

    11.7.3. Financial Overview

    11.7.4. Key Developments

    11.7.5. SWOT Analysis

    11.7.6. Key Strategies

    11.8. Vanda Pharmaceuticals

    11.8.1. Company Overview

    11.8.2. Product Overview

    11.8.3. Financial Overview

    11.8.4. Key Developments

    11.8.5. SWOT Analysis

    11.8.6. Key Strategies

    11.9. Allergan/ Geodon Ritcher

    11.9.1. Company Overview

    11.9.2. Product Overview

    11.9.3. Financial Overview

    11.9.4. Key Developments

    11.9.5. SWOT Analysis

    11.9.6. Key Strategies

    11.10. Others

    12. APPENDIX

    12.1. References

    12.2. Related Reports


    LIST OF TABLES

    TABLE 1 GLOBAL SCHIZOPHRENIA MARKET SYNOPSIS, 2020-2027

    TABLE 2 GLOBAL SCHIZOPHRENIA MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 6 GLOBAL SCHIZOPHRENIA MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 7 NORTH AMERICA: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 8 NORTH AMERICA: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 9 NORTH AMERICA: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 10 US: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 11 US: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 12 US: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 13 CANADA: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 14 CANADA: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 15 CANADA: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 16 LATIN AMERICA: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 17 LATIN AMERICA: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 18 LATIN AMERICA: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 19 EUROPE: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 20 EUROPE: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 21 EUROPE: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 22 WESTERN EUROPE: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 23 WESTERN EUROPE: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 24 WESTERN EUROPE: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 25 EASTERN EUROPE: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 26 EASTERN EUROPE: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 27 EASTERN EUROPE: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 28 ASIA-PACIFIC: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 29 ASIA-PACIFIC: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 30 ASIA-PACIFIC: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 31 MIDDLE EAST & AFRICA: SCHIZOPHRENIA MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 32 MIDDLE EAST & AFRICA: SCHIZOPHRENIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 33 MIDDLE EAST & AFRICA: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)


    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL SCHIZOPHRENIA MARKET

    FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL SCHIZOPHRENIA MARKET

    FIGURE 4 GLOBAL SCHIZOPHRENIA MARKET SHARE, BY TYPE, 2020 (%)

    FIGURE 5 GLOBAL SCHIZOPHRENIA MARKET SHARE, BY TREATMENT, 2020 (%)

    FIGURE 6 GLOBAL SCHIZOPHRENIA MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2020 (%)

    FIGURE 7 GLOBAL SCHIZOPHRENIA MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 8 AMERICAS: SCHIZOPHRENIA MARKET SHARE BY REGION, 2020 (%)

    FIGURE 9 NORTH AMERICA: SCHIZOPHRENIA MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 10 EUROPE: SCHIZOPHRENIA MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 11 WESTERN EUROPE: SCHIZOPHRENIA MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 12 ASIA-PACIFIC: SCHIZOPHRENIA MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 13 MIDDLE EAST & AFRICA: SCHIZOPHRENIA MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 14 GLOBAL SCHIZOPHRENIA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 15 JOHNSON & JOHNSON: KEY FINANCIALS

    FIGURE 16 JOHNSON & JOHNSON: SEGMENTAL REVENUE

    FIGURE 17 JOHNSON & JOHNSON: REGIONAL REVENUE

    FIGURE 18 ASTRAZENECA: KEY FINANCIALS

    FIGURE 19 ASTRAZENECA: SEGMENTAL REVENUE

    FIGURE 20 ASTRAZENECA: REGIONAL REVENUE

    FIGURE 21 ELI LILLY: KEY FINANCIALS

    FIGURE 22 ELI LILLY: SEGMENTAL REVENUE

    FIGURE 23 ELI LILLY: REGIONAL REVENUE

    FIGURE 24 ALKERMES: KEY FINANCIALS

    FIGURE 25 ALKERMES: SEGMENTAL REVENUE

    FIGURE 26 ALKERMES: REGIONAL REVENUE

    FIGURE 27 SUMITOMO DAINIPPON PHARMA: KEY FINANCIALS

    FIGURE 28 SUMITOMO DAINIPPON PHARMA: SEGMENTAL REVENUE

    FIGURE 29 SUMITOMO DAINIPPON PHARMA: REGIONAL REVENUE

    FIGURE 30 PFIZER: KEY FINANCIALS

    FIGURE 31 PFIZER: SEGMENTAL REVENUE

    FIGURE 32 PFIZER: REGIONAL REVENUE

    FIGURE 33 VANDA PHARMACEUTICALS: KEY FINANCIALS

    FIGURE 34 VANDA PHARMACEUTICALS: SEGMENTAL REVENUE

    FIGURE 35 VANDA PHARMACEUTICALS: REGIONAL REVENUE

    FIGURE 36 ALLERGAN/ GEODON RITCHER: KEY FINANCIALS

    FIGURE 37 ALLERGAN/ GEODON RITCHER: SEGMENTAL REVENUE

    FIGURE 38 ALLERGAN/ GEODON RITCHER: REGIONAL REVENUE